Pharvaris N.V. Ordinary Shares (PHVS) Stock Price
PHVSStock
$35.32+54.64%52W
Market Cap$2.48B
P/E—
PEG Ratio—
Div yield—
Beta-2.65
PHVS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)14.44%
Price vs S&P 500 (4W)7.98%
VGM Score65.51
PHVS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.76 | -$0.81 | -7.09%(-$0.06) | |
| Q4 2025 | -$0.71 | -$0.82 | -15.41%(-$0.10) | |
| Q3 2025 | -$0.78 | -$0.70 | +10.71%(+$0.08) | |
| Q2 2025 | -$0.89 | -$0.96 | -8.46%(-$0.07) |
PHVS Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.35
4.35
4.35
4.33
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PHVSPharvaris N.V. Ordinary Shares | — | — | B | $35.32 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Pharvaris N.V. Ordinary Shares
Pharvaris is a late-stage biopharmaceutical company developing deucrictibant, an oral bradykinin B2 receptor antagonist designed to prevent and treat hereditary angioedema (HAE) attacks. The company has demonstrated positive efficacy data in Phase 2 studies and is currently enrolling pivotal Phase 3 trials for both treatment and prevention indications.